NO984555L - T1- Lever - Google Patents

T1- Lever

Info

Publication number
NO984555L
NO984555L NO984555A NO984555A NO984555L NO 984555 L NO984555 L NO 984555L NO 984555 A NO984555 A NO 984555A NO 984555 A NO984555 A NO 984555A NO 984555 L NO984555 L NO 984555L
Authority
NO
Norway
Prior art keywords
contrast
magnetic particles
weighted image
vasculature
organ
Prior art date
Application number
NO984555A
Other languages
English (en)
Other versions
NO984555D0 (no
Inventor
Anne Kjersti Fahlvik
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of NO984555L publication Critical patent/NO984555L/no
Publication of NO984555D0 publication Critical patent/NO984555D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen omfatter en metode for kontrastforsterket MR angiografi av menneskelig eller ikke-menneskelig legeme, nevnte metode omfatter å administrere i vaskulaturen en kontrasteffektiv mengde av kontrastmiddel som omfatter magnetiske partikler med en r2/n forhold ikke større enn 5, og når en stor nok mengde magnetiske partikler er igjen i vaskulaturen til å gi en positiv kontrastforsterkining derav i et T] vektet bilde mens nok magnetiske partikler er tatt opp i et organ i det retikuloendoteliale system til å gi en negativ kontrastforsterkning derav i nevnte TI vektede bilde, og generere et TI vektet magnetisk resonans bilde av minst nevnte organ.
NO984555A 1996-04-01 1998-09-29 T1- Lever NO984555D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/625,223 US5855868A (en) 1996-04-01 1996-04-01 Method of T1 -weighted resonance imaging of RES organs
PCT/GB1997/000886 WO1997036617A2 (en) 1996-04-01 1997-03-27 Method of t1-weighted magnetic resonance imaging of res organs

Publications (2)

Publication Number Publication Date
NO984555L true NO984555L (no) 1998-09-29
NO984555D0 NO984555D0 (no) 1998-09-29

Family

ID=24505090

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984555A NO984555D0 (no) 1996-04-01 1998-09-29 T1- Lever

Country Status (14)

Country Link
US (1) US5855868A (no)
EP (1) EP0896546B1 (no)
JP (1) JP4361970B2 (no)
KR (1) KR20000005194A (no)
CN (1) CN1219135A (no)
AT (1) ATE228017T1 (no)
AU (1) AU704926B2 (no)
CA (1) CA2250818A1 (no)
DE (1) DE69717269T2 (no)
EA (1) EA000796B1 (no)
ES (1) ES2188924T3 (no)
IL (1) IL126412A0 (no)
NO (1) NO984555D0 (no)
WO (1) WO1997036617A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
CN1151846C (zh) 1996-08-05 2004-06-02 舍林公开股份有限公司 核磁共振断层扫描成像用造影剂的制备方法
US7082326B2 (en) * 2000-03-31 2006-07-25 Amersham Health As Method of magnetic resonance imaging
WO2001074245A1 (en) * 2000-03-31 2001-10-11 Amersham Health As Method of magnetic resonance imaging
KR20020075513A (ko) * 2001-03-24 2002-10-05 조용덕 전기분해법을 이용한 폐수의 처리방법
DE102004022061A1 (de) 2004-05-05 2005-12-08 Siemens Ag Verfahren zur verbesserten interventionallen Bildgebung in der Magnet-Resonanz-Tomographie
US20100259259A1 (en) * 2005-09-21 2010-10-14 Markus Zahn Systems and methods for tuning properties of nanoparticles
KR20090038337A (ko) * 2007-10-15 2009-04-20 재단법인서울대학교산학협력재단 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제
WO2016004061A1 (en) * 2014-06-30 2016-01-07 University Of Washington Mri signal supression agents, compositions, and methods
US10466326B2 (en) * 2015-05-15 2019-11-05 Stc. Unm Quantitative [Fe]-MRI (femri) of anti-PSMA-conjugated SPIONs based on PSMA expression levels
WO2021052850A1 (de) * 2019-09-18 2021-03-25 Bayer Aktiengesellschaft Erzeugung von mrt-aufnahmen der leber

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935187A (en) * 1973-10-19 1976-01-27 Standard Brands Incorporated Process for depolymerizing amylaceous polymers
WO1983001738A1 (en) * 1981-11-12 1983-05-26 SCHRÖDER, Ulf Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US5069216A (en) * 1986-07-03 1991-12-03 Advanced Magnetics Inc. Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
WO1992012735A1 (fr) * 1991-01-19 1992-08-06 Meito Sangyo Kabushiki Kaisha Composition contenant des particules ultra fines d'oxyde de metal magnetique
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
DE69207589T2 (de) * 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
ATE156706T1 (de) * 1993-03-17 1997-08-15 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
RU2147243C1 (ru) * 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
EP0877630B1 (en) * 1996-01-10 2005-03-23 Amersham Health AS Contrast media

Also Published As

Publication number Publication date
AU2172197A (en) 1997-10-22
ES2188924T3 (es) 2003-07-01
CA2250818A1 (en) 1997-10-09
US5855868A (en) 1999-01-05
WO1997036617A3 (en) 1998-02-26
EA199800881A1 (ru) 1999-04-29
JP2000507567A (ja) 2000-06-20
WO1997036617A2 (en) 1997-10-09
IL126412A0 (en) 1999-05-09
EP0896546A2 (en) 1999-02-17
ATE228017T1 (de) 2002-12-15
DE69717269T2 (de) 2003-08-28
JP4361970B2 (ja) 2009-11-11
EP0896546B1 (en) 2002-11-20
DE69717269D1 (de) 2003-01-02
AU704926B2 (en) 1999-05-06
KR20000005194A (ko) 2000-01-25
EA000796B1 (ru) 2000-04-24
NO984555D0 (no) 1998-09-29
CN1219135A (zh) 1999-06-09

Similar Documents

Publication Publication Date Title
ZA945038B (en) Image contrast enhancing composition
ATE142891T1 (de) Vaskulares magnetisches bildformungsverfahren
NO173429C (no) Anvendelse av ferromagnetiske partikler i kontrastmidler for NMR-avbildning
NO984555D0 (no) T1- Lever
CA2077760A1 (en) Magnetic resonance imaging
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
DK0620743T3 (da) Kontrastmidler bestående af galactosepartikler og en amfifil carboxylsyre
KR930700161A (ko) 진단 작용제(Diagnostic Agents)
DK0586524T3 (no)
MY110186A (en) The use of tyloxapol as a nanoparticle stabilizer and dispersant.
DE69334293D1 (de) Verfahren und Kit zur Bilderzeugung von Organen und Geweben, worin markierte Antikörper verwendet werden
ATE151620T1 (de) Gefässimplantat
DE69117541D1 (de) Implantat mit durchgangsöffnung
ATE169200T1 (de) Kontrastmittel
GB9716365D0 (en) Improvements in or relating to magnetic resonance imaging
AU2320392A (en) Hydroxamate and hydrazide derivatives of polyamines and their medical use as chelating agents
WO2001019409A3 (en) Method of tumor imaging
ATE132758T1 (de) Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
CA2271735A1 (en) Magnetic resonance blood pool agents
袁春波 et al. Effects of metal ions on the conformation of polar headgroup of sphingomyelin bilayer
UA41932C2 (uk) Засіб для ямр-томографії
of Man An act (Chapter No. 3) to prohibit commercial dealings in human organs intended for transplanting; to prohibit the transplanting of such organs between persons who are not genetically related; and for connected purposes. Dated 16 March 1993.(The Human Organ Transplants Act 1993)
NO904337L (no) Kontrastmidler for magnetisk resonansavbildning.
KR930700165A (ko) 조영제

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application